{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:29:05Z","timestamp":1785421745413,"version":"3.56.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","award":["89251"],"award-info":[{"award-number":["89251"]}],"id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SIRIC Montpellier Cancer","award":["18004"],"award-info":[{"award-number":["18004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Early palliative care improves the quality of life (QoL) and survival in patients with cancer; however, its effects in patients with glioblastoma remain unclear. The GLIOSUPPORT study assessed the feasibility (adherence; primary objective) of an early palliative care program integrated into the standard glioblastoma care pathway. Secondary objectives included the description of the patients\u2019 characteristics, QoL, and neuropsychological changes over time, end-of-life decisions, end-of-life treatments, and family carers\u2019 perceptions\/experiences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This interventional, prospective, longitudinal, feasibility study was conducted in a French comprehensive cancer center. Thirty-five patients with newly diagnosed glioblastoma were required to reach an adherence rate of 60%. Adherence was defined as going to 3 palliative care visits scheduled every 12 weeks. Baseline characteristics were compared in patients who did and did not adhere to the palliative care program. Minimal clinically important differences and cut-offs were used to quantify QoL changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The adherence rate was 60% (95% CI [42.1%-76.1%]), indicating that the program was feasible. Visual disturbances, communication\/initiation deficits, and anxiety were more frequent in the group that did not adhere to the program. Emotional and social functioning, pain, appetite loss, constipation, and headache increased over time (clinically significant differences), whereas neuropsychological disturbances did not change. Half of the participants identified a family proxy and 8.6% wrote advance directives. One month before death, 28.6% of patients were receiving cancer treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Integrating early palliative care in glioblastoma management is feasible. The potential benefits on QoL, mood, and survival must now be evaluated in a larger randomized controlled trial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf064","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:21:44Z","timestamp":1746793304000},"source":"Crossref","is-referenced-by-count":5,"title":["Integrated early palliative care for patients with newly diagnosed glioblastoma: The GLIOSUPPORT feasibility study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-4777","authenticated-orcid":false,"given":"Michel","family":"Fabbro","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-3874","authenticated-orcid":false,"given":"Muriel","family":"Thomaso","sequence":"additional","affiliation":[{"name":"Palliative and Supportive Care Department, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1384-1709","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Darlix","sequence":"additional","affiliation":[{"name":"Institute of Functional Genomics, University of Montpellier, CNRS, INSERM , Montpellier ,","place":["France"]},{"name":"Department of Medical Oncology, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8016-3015","authenticated-orcid":false,"given":"Virginie","family":"Perotin","sequence":"additional","affiliation":[{"name":"Palliative and Supportive Care Department, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3960-1631","authenticated-orcid":false,"given":"Caroline","family":"Gallay","sequence":"additional","affiliation":[{"name":"Palliative and Supportive Care Department, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Charissoux","sequence":"additional","affiliation":[{"name":"Department of Oncological Radiotherapy, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Chantal","family":"Granier","sequence":"additional","affiliation":[{"name":"Palliative and Supportive Care Department, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3054-8774","authenticated-orcid":false,"given":"Nabila","family":"Bouazza","sequence":"additional","affiliation":[{"name":"Clinical Research and Innovation Department, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Champoiral","sequence":"additional","affiliation":[{"name":"Palliative and Supportive Care Department, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Coutant","sequence":"additional","affiliation":[{"name":"Palliative and Supportive Care Department, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jarlier","sequence":"additional","affiliation":[{"name":"Biometrics Unit, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-0791","authenticated-orcid":false,"given":"Estelle","family":"Guerdoux","sequence":"additional","affiliation":[{"name":"Institute Desbrest of Epidemiology and Public Health, INSERM UMR 1318, University Montpellier , Montpellier ,","place":["France"]},{"name":"Palliative and Supportive Care Department, Montpellier Cancer Institute, University of Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"Suppl 5","key":"2025050908213794000_CIT0001","first-page":"vv1","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009\u20132013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol"},{"issue":"4","key":"2025050908213794000_CIT0002","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"2025050908213794000_CIT0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-018-03065-z","article-title":"Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study","volume":"142","author":"Fabbro-Peray","year":"2019","journal-title":"J Neurooncol."},{"issue":"3","key":"2025050908213794000_CIT0004","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11060-016-2318-3","article-title":"Epidemiology for primary brain tumors: a nationwide population-based study","volume":"131","author":"Darlix","year":"2017","journal-title":"J Neurooncol."},{"issue":"10","key":"2025050908213794000_CIT0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"8","key":"2025050908213794000_CIT0006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med."},{"issue":"10172","key":"2025050908213794000_CIT0007","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet."},{"issue":"5","key":"2025050908213794000_CIT0008","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/ijms25052529","article-title":"Glioblastoma therapy: past, present and future","volume":"25","author":"Obrador","year":"2024","journal-title":"Int J Mol Sci."},{"issue":"3","key":"2025050908213794000_CIT0009","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eurpsy.2005.05.008","article-title":"Gender difference in relation to depression and quality of life among patients with a primary brain tumor","volume":"21","author":"Mainio","year":"2006","journal-title":"Eur Psych"},{"key":"2025050908213794000_CIT0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clineuro.2015.10.002","article-title":"Prognostic implications of epilepsy in glioblastomas","volume":"139","author":"Toledo","year":"2015","journal-title":"Clin Neurol Neurosurg."},{"issue":"12","key":"2025050908213794000_CIT0011","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","article-title":"Health-related quality of life in patients with glioblastoma: a randomised controlled trial","volume":"6","author":"Taphoorn","year":"2005","journal-title":"Lancet Oncol."},{"issue":"12","key":"2025050908213794000_CIT0012","doi-asserted-by":"crossref","first-page":"e28592","DOI":"10.1371\/journal.pone.0028592","article-title":"Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study","volume":"6","author":"Jakola","year":"2011","journal-title":"PLoS One."},{"issue":"3","key":"2025050908213794000_CIT0013","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1200\/JCO.2000.18.3.646","article-title":"Cognitive function as a predictor of survival in patients with recurrent malignant glioma","volume":"18","author":"Meyers","year":"2000","journal-title":"J Clin Oncol."},{"issue":"2","key":"2025050908213794000_CIT0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.radonc.2017.07.027","article-title":"The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma","volume":"125","author":"Flechl","year":"2017","journal-title":"Radiother Oncol"},{"issue":"1","key":"2025050908213794000_CIT0015","doi-asserted-by":"crossref","first-page":"e12410","DOI":"10.1111\/ecc.12410","article-title":"Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature","volume":"28","author":"Bergo","year":"2019","journal-title":"Eur J Cancer Care (Engl)."},{"issue":"12","key":"2025050908213794000_CIT0016","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00520-014-2384-z","article-title":"Glioblastoma multiforme from diagnosis to death: a prospective, hospital-based, cohort, pilot feasibility study of patient reported symptoms and needs","volume":"22","author":"Golla","year":"2014","journal-title":"Supp Care Cancer"},{"issue":"3","key":"2025050908213794000_CIT0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-005-7020-9","article-title":"Prospective study of quality of life in adults with newly diagnosed high-grade gliomas","volume":"76","author":"Brown","year":"2006","journal-title":"J Neurooncol."},{"issue":"3","key":"2025050908213794000_CIT0018","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.bjc.6603876","article-title":"The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC brain tumour and radiation oncology groups and NCIC clinical trials group study","volume":"97","author":"Mauer","year":"2007","journal-title":"Br J Cancer."},{"issue":"6","key":"2025050908213794000_CIT0019","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/2014.9.FOCUS14493","article-title":"Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients. FOC","volume":"37","author":"Pompili","year":"2014","journal-title":"Neurosurg Focus."},{"issue":"3","key":"2025050908213794000_CIT0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-013-1069-7","article-title":"The caregivers\u2019 perspective on the end-of-life phase of glioblastoma patients","volume":"112","author":"Flechl","year":"2013","journal-title":"J Neurooncol."},{"key":"2025050908213794000_CIT0021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-824535-4.00011-2","article-title":"Palliative care in brain tumors","volume":"191","author":"Walbert","year":"2023","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"2025050908213794000_CIT0022","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/CCO.0000000000001045","article-title":"Interventions aiming to improve advance care planning uptake in oncology: a scoping review of recent randomized controlled trials","volume":"36","author":"Libert","year":"2024","journal-title":"Curr Opin Oncol."},{"issue":"4","key":"2025050908213794000_CIT0023","first-page":"299","article-title":"Trends and outcomes of early and late palliative care consultation for adult patients with glioblastoma: A SEER-Medicare retrospective study","volume":"9","author":"Wu","year":"2022","journal-title":"Neurooncol. Pract."},{"issue":"1","key":"2025050908213794000_CIT0024","first-page":"115","article-title":"A retrospective survey of the last 3 months of life in patients carrying glioblastoma: clinical treatments and profiles","volume":"8","author":"Rivoirard","year":"2018","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"2025050908213794000_CIT0025","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/cancers13122867","article-title":"Palliative care service utilization and advance care planning for adult glioblastoma patients: a systematic review","volume":"13","author":"Wu","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"2025050908213794000_CIT0026","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jama.2009.1198","article-title":"Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial","volume":"302","author":"Bakitas","year":"2009","journal-title":"JAMA."},{"issue":"17","key":"2025050908213794000_CIT0027","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.2006.09.2627","article-title":"Phase II study: integrated palliative care in newly diagnosed advanced non\u2013small-cell lung cancer patients. JCO","volume":"25","author":"Temel","year":"2007","journal-title":"J Clin Oncol."},{"issue":"17","key":"2025050908213794000_CIT0028","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1200\/JCO.2010.32.4459","article-title":"Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non\u2013small-cell lung cancer: results of a randomized study of early palliative care","volume":"29","author":"Temel","year":"2011","journal-title":"J Clin Oncol."},{"issue":"6","key":"2025050908213794000_CIT0029","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/02692163231152526","article-title":"Comparison of healthcare utilization and life-sustaining interventions between patients with glioblastoma receiving palliative care or not: a population-based study","volume":"37","author":"Shieh","year":"2023","journal-title":"Palliat Med."},{"issue":"9","key":"2025050908213794000_CIT0030","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/cncr.24206","article-title":"Supportive versus palliative care: what\u2019s in a name","volume":"115","author":"Fadul","year":"2009","journal-title":"Cancer."},{"issue":"1","key":"2025050908213794000_CIT0031","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice guideline update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J Clin Oncol."},{"issue":"3","key":"2025050908213794000_CIT0032","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/neuonc\/noac216","article-title":"Palliative care and end-of-life care in adults with malignant brain tumors","volume":"25","author":"Koekkoek","year":"2022","journal-title":"Neuro Oncol"},{"issue":"6","key":"2025050908213794000_CIT0033","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","article-title":"European Association for Neuro-oncology (EANO) guidelines for palliative care in adults with glioma","volume":"18","author":"Pace","year":"2017","journal-title":"Lancet Oncol."},{"issue":"25","key":"2025050908213794000_CIT0034","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1200\/JCO.2010.29.5618","article-title":"Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care","volume":"28","author":"Bruera","year":"2010","journal-title":"J Clin Oncol."},{"issue":"9","key":"2025050908213794000_CIT0035","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.18.02123","article-title":"Models of palliative care delivery for patients with cancer","volume":"38","author":"Hui","year":"2020","journal-title":"J Clin Oncol."},{"issue":"4","key":"2025050908213794000_CIT0036","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCO.0000000000000733","article-title":"Models of supportive care in oncology","volume":"33","author":"Hui","year":"2021","journal-title":"Curr Opin Oncol."},{"issue":"1","key":"2025050908213794000_CIT0037","first-page":"19","article-title":"Reporting standards in randomized controlled trials involving neuro-oncology caregivers: a systematic review report from the RANO-cares working group","volume":"12","author":"Boele","year":"2024","journal-title":"Neurooncol. Pract.."},{"issue":"3","key":"2025050908213794000_CIT0038","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1089\/jpm.2013.0047","article-title":"Respecting choices \u00ae and advance directives in a diverse community","volume":"17","author":"Pecanac","year":"2014","journal-title":"J Palliat Med."},{"issue":"1","key":"2025050908213794000_CIT0039","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/CPJ.0000000000001123","article-title":"Advance directive and POLST documentation in decedents with dementia at a memory care center: the importance of early advance care planning","volume":"12","author":"Naasan","year":"2022","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"2025050908213794000_CIT0040","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11060-018-2800-1","article-title":"Clinical routine assessment of palliative care symptoms and concerns and caregiver burden in glioblastoma patients: an explorative field study","volume":"138","author":"Seibl-Leven","year":"2018","journal-title":"J Neurooncol."},{"issue":"5","key":"2025050908213794000_CIT0041","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"2025050908213794000_CIT0042","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"Eur J Cancer."},{"issue":"1","key":"2025050908213794000_CIT0043","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-3999(96)00216-4","article-title":"International experiences with the hospital anxiety and depression scale\u2014a review of validation data and clinical results","volume":"42","author":"Herrmann","year":"1997","journal-title":"J Psychosom Res."},{"issue":"Jan","key":"2025050908213794000_CIT0044","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1192\/bjp.156.1.79","article-title":"Screening for adjustment disorders and major depressive disorders in cancer in-patients","volume":"156","author":"Razavi","year":"1990","journal-title":"Br J Psychiatry."},{"key":"2025050908213794000_CIT0045","first-page":"77","article-title":"Mental status examination for organic mental","volume-title":"Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians","author":"Mattis","year":"1976"},{"issue":"5","key":"2025050908213794000_CIT0046","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1533317511412046","article-title":"Mattis Dementia Rating Scale 2: screening for MCI and dementia","volume":"26","author":"Matteau","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen."},{"issue":"5 Suppl","key":"2025050908213794000_CIT0047","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00005650-197605001-00018","article-title":"12. Index of ADL","volume":"14","author":"Katz","year":"1976","journal-title":"Med Care."},{"issue":"21","key":"2025050908213794000_CIT0048","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025050908213794000_CIT0049","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/neuonc\/noab037","article-title":"Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients","volume":"23","author":"Dirven","year":"2021","journal-title":"Neuro-Oncology."},{"issue":"9","key":"2025050908213794000_CIT0050","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdq726","article-title":"Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients","volume":"22","author":"Maringwa","year":"2011","journal-title":"Ann Oncol"},{"issue":"7","key":"2025050908213794000_CIT0051","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1080\/13854046.2013.825010","article-title":"Normative data for the dementia rating scale-2 in the French-Quebec population","volume":"27","author":"Lavoie","year":"2013","journal-title":"Clin Neuropsychol."},{"issue":"1","key":"2025050908213794000_CIT0052","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11060-017-2487-8","article-title":"End of life care for glioblastoma patients at a large academic cancer center","volume":"134","author":"Kuchinad","year":"2017","journal-title":"J Neurooncol."},{"issue":"3","key":"2025050908213794000_CIT0053","first-page":"182","article-title":"Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care","volume":"4","author":"Hemminger","year":"2017","journal-title":"Neurooncol. Pract."},{"issue":"5","key":"2025050908213794000_CIT0054","first-page":"454","article-title":"Exploring the clinical utility of a brief screening measure of unmet supportive care needs in people with high-grade glioma","volume":"10","author":"Campbell","year":"2023","journal-title":"Neurooncol. Pract."},{"issue":"8","key":"2025050908213794000_CIT0055","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1200\/JCO.2016.70.5046","article-title":"Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial","volume":"35","author":"Temel","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"2025050908213794000_CIT0056","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3171\/2015.4.JNS15194","article-title":"Quality of survival the 1st year with glioblastoma: a longitudinal study of patient-reported quality of life","volume":"124","author":"Sagberg","year":"2016","journal-title":"J Neurosurg."},{"issue":"6","key":"2025050908213794000_CIT0057","first-page":"733","article-title":"Prospective assessment of end-of-life symptoms and quality of life in patients with high-grade glioma","volume":"11","author":"Walbert","year":"2024","journal-title":"Neurooncol Pract."},{"issue":"6","key":"2025050908213794000_CIT0058","first-page":"599","article-title":"Determining medical decision-making capacity in brain tumor patients: why and how","volume":"7","author":"Pace","year":"2020","journal-title":"Neurooncol Pract."},{"issue":"4","key":"2025050908213794000_CIT0059","first-page":"335","article-title":"Depression and anxiety in glioma patients","volume":"10","author":"van der Meer","year":"2023","journal-title":"Neurooncol Pract."},{"issue":"2","key":"2025050908213794000_CIT0060","first-page":"62","article-title":"International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-oncology, the European Association of Neuro-oncology, and the Society for Neuro-oncology","volume":"2","author":"Walbert","year":"2015","journal-title":"Neurooncol Pract."},{"key":"2025050908213794000_CIT0061","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/B978-0-12-824535-4.00006-9","article-title":"Education in neuropalliative care","volume":"191","author":"Kramer","year":"2023","journal-title":"Handb Clin Neurol"},{"issue":"8","key":"2025050908213794000_CIT0062","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"2025050908213794000_CIT0063","first-page":"vdae084","article-title":"Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: a feasibility study","volume":"6","author":"Darlix","year":"2024","journal-title":"Neurooncol Adv."},{"issue":"3","key":"2025050908213794000_CIT0064","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/arclin\/acx131","article-title":"Neuropsychological practice in the oncology setting","volume":"33","author":"Noll","year":"2018","journal-title":"Arch Clin Neuropsychol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf064\/62768509\/vdaf064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf064\/62768509\/vdaf064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:21:54Z","timestamp":1746793314000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf064\/8097632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf064","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf064"}}